Q-omics provides the consensus-scored RN7SKP168 profile across patient tissues and cancer cell-line models. RN7SKP168 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RN7SKP168 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RN7SKP168 RNA expression shows 12,163 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LIHC, LUSC, and COAD as cancer lineages where RN7SKP168 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP168 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP168 survival associations across molecular data types. RN7SKP168 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP168 RNA expression–survival associations across cancer types. High RN7SKP168 expression shows unfavorable associations in LIHC, PAAD, GBM, SKCM, SARC and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RN7SKP168 RNA expression.
This table summarizes RN7SKP168 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP168. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP168 shows higher tumor expression in LUSC, HNSC and LIHC. The LUSC box plot shows higher RN7SKP168 RNA expression in tumor versus normal tissue (log2 FC = +0.112, t-test p < 0.001).
This table shows molecular features associated with RN7SKP168 in patient tissues and cancer cell lines. In patient samples, RN7SKP168 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
